The partnership employs KineMed’s new dynamic proteomics technology platform to map the impact of potential drug candidates on specific metabolic pathways. KineMed president, co-founder and chief science officer
Both the companies have not disclosed the financial terms of the agreement. Genmab chief executive officer Jan van de Winkel said the company is happy to enter its
The company said that the new licensed patents include protection for human therapeutic uses of NR and build upon the patents licensed from Dartmouth in 2012 for other
In Canada, standard review takes 18 months or more and priority review, which is granted to promising medicines that address life-threatening or severely debilitating conditions, shortens the review
The company said that results were also observed in patients with ALK+ NSCLC who entered the trial with brain metastases. Seoul National University Hospital lead investigator Dong-Wan Kim
The European Commission has also granted orphan drug designation for HETLIOZ to treat Non-24 in blind people with no light perception. In January 2014, HETLIOZ was approved by
Portfolio of Asana includes multiple compounds for oncology and pain indications that are ready to enter clinical trials. Asana chief executive officer Sandeep Gupta said the company’s mission
Since 2007, BMS has been working with Syngene and its corporate parent, Biocon, to develop integrated capabilities in medicinal and process chemistry, biology, biotechnology, biomarkers, drug metabolism and
The company expects lab results, pharmacokinetic studies, and analysis to take about two months. If the results shows bioequivalence of Prurisol with Abacavir Sulfate, Cellceutix will then schedule
Additionally, the company had recently received a Notice of Allowance from the US Patent & Trademark Office for its Emesyl trademark. The NDC number and trademark Notice of
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.